Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Reason given: Protocol closed to accrual early due to PI retirement.
Key facts
- Where
- Brooklyn and New York, United StatesSee the 4 sites
Where in United States
- Kings County Hopsital CenterBrooklyn, United StatesNo longer taking part
- SUNY Downstate Medical Center (DMC)Brooklyn, United StatesNo longer taking part
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, United StatesNo longer taking part
- Weill Medical College of Cornell UniversityNew York, United StatesNo longer taking part
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT00773773
- Record updated
- 4 September 2024
- Original description
This is a prospective, serum proteomics study of men who are to undergo prostate biopsy. The purpose is to determine if proteomic profiles can be used to distinguish between men with prostate cancer on biopsy from men with no cancer on biopsy.Read full original descriptionShow less
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
This is a prospective, serum proteomics study of men who are to undergo prostate biopsy. The purpose is to determine if proteomic profiles can be used to distinguish between men with prostate cancer on biopsy from men with no cancer on biopsy.
Inclusion: Men aged 18 years or older; Have a PSA level between 2 and 10 ng/ml; May or may not have an abnormal digital rectal examination; Scheduled for trans-rectal ultrasound (TRUS) guided systematic prostate biopsy as part of routine medical care. All sites (Department of Urology at SUNY Downstate Medical Center, Brooklyn, the Department of Urology, New York Presbyterian Hospital, Weill Medical College of Cornell University, Manhattan and the Department of Urology, Kings County Hospital) will perform a standardized 14 core biopsy protocol; Signed, informed consent; Patient must be able to attend the pre-biopsy blood draw.
Exclusion: Any period of prior/current treatment with hormonal therapy (LHRH agonist/antagonist,antiandrogen, 5-alpha-reductase inhibitor); Prior pelvic radiation; A period of less than 6 months prior/current treatment with an alpha-blocker; Previous diagnosis of prostate cancer.